BioSpace News Archive

Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary genetic engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced the appointment of three new members to its Scientific Advisory Board (SAB)

MY01 Inc. is on a mission to empower healthcare professionals with the ability to pre-empt severe medical conditions, improving patient outcomes. MY01 inc. today announced U.S. Food and Drug Administration 510(k) clearance for the MY01 Continuous Compartment Pressure Monitor with full Bluetooth capabilities.

Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the Company will release its first quarter 2021 financial results before the market opens on Thursday, May 13, 2021

Aditx Therapeutics, Inc. (Aditxt) (the “Company”) (Nasdaq: ADTX), a biotech innovation company focused on improving the health of the immune system, today announced that Meridian Health Services Network (Meridian HSN) will offer AditxtScore™ for COVID-19 to its network of healthcare provider partners.

LIPAC Oncology LLC., a pharmaceutical company utilizing its liposome-bound nano-technology platform to provide precision targeted cancer drugs for the treatment of multiple tumor types, today announced the appointment of Josh Hamermesh as an independent board director.

Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with kidney and cardiorenal diseases, today reported business highlights and financial results for the first quarter ended March 31, 2021 .

Amyris, Inc., a leading synthetic biotechnology company active in the Clean Health and Beauty markets through its consumer brands, announced financial results for its first quarter ended March 31, 2021.

Conference Call and Webcast Scheduled for Thursday, May 13, 2021 at 8:30 AM ET

Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced the appointment of Michael Swartzburg as Chief Financial Officer.

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “Company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced the appointment of Lawrence Weiss, M.D. as Chief Medical Officer, reporting to the Company’s Chief Executive Officer, Ming Hsieh